Clinical Trials Browser

Phase 3 × Has results × Thoracic × Clear all

NCT03043872 2026-04-22

CASPIAN

Phase 3 Active not recruiting

987 enrolled 42 charts 1 FDA

Small Cell Lung Carcinoma

NCT04487080 2026-04-22

MARIPOSA

Phase 3 Active not recruiting

1,074 enrolled 13 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT04988295 2026-04-22

MARIPOSA-2

Phase 3 Active not recruiting

776 enrolled 13 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT02296125 2026-04-21

FLAURA

Phase 3 Completed

674 enrolled 21 charts 1 FDA

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer

NCT03710876 2026-04-21

INFINITE

Phase 3 Completed

53 enrolled 23 charts

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT04765059 2026-04-21

COMPEL

Phase 3 Active not recruiting

98 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung

NCT03811002 2026-04-13

Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)

Phase 3 Active not recruiting

544 enrolled 29 charts

Lung Neoplasms

NCT04538664 2026-04-13

PAPILLON

Phase 3 Active not recruiting

308 enrolled 12 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT05388669 2026-04-13

PALOMA-3

Phase 3 Active not recruiting

418 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung

NCT04256421 2026-04-03

SKYSCRAPER-02

Phase 3 Completed

490 enrolled 33 charts

Small Cell Lung Carcinoma

NCT04205812 2026-03-31

POD1UM-304

Phase 3 Active not recruiting

583 enrolled 22 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT02511106 2026-03-30

ADAURA

Phase 3 Active not recruiting

682 enrolled 20 charts 2 FDA

Stage IB-IIIA Non-small Cell Lung Carcinoma

NCT04303780 2026-03-27

Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).

Phase 3 Active not recruiting

345 enrolled 11 charts

KRAS p, G12c Mutated /Advanced Metastatic NSCLC

NCT04656652 2026-03-24

Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)

Phase 3 Active not recruiting

605 enrolled 14 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT02838420 2026-03-18

A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase 3 Active not recruiting

187 enrolled 14 charts

Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer

NCT02973789 2026-03-18

Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)

Phase 3 Completed

291 enrolled 22 charts

Carcinoma, Non-Small-Cell Lung

NCT02504372 2026-03-17

PEARLS

Phase 3 Completed

1,177 enrolled 21 charts 2 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT03164616 2026-03-13

POSEIDON

Phase 3 Active not recruiting

1,186 enrolled 26 charts 2 FDA

Non Small Cell Lung Cancer NSCLC

NCT03003962 2026-03-11

Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)

Phase 3 Active not recruiting

669 enrolled 54 charts

Non Small Cell Lung Carcinoma NSCLC

NCT05091567 2026-03-10

IMforte

Phase 3 Active not recruiting

660 enrolled 23 charts 2 FDA

Small Cell Lung Carcinoma

NCT04222972 2026-03-05

AcceleRET-Lung

Phase 3 Terminated

223 enrolled 18 charts

Head & NeckThoracic

Adenocarcinoma, Bronchial Diseases, Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT02453282 2026-03-02

MYSTIC

Phase 3 Active not recruiting

1,118 enrolled 40 charts

Carcinoma, Non-Small-Cell Lung

NCT03706690 2026-03-02

PACIFIC-5

Phase 3 Active not recruiting

407 enrolled 22 charts

Carcinoma, Non-Small-Cell Lung

NCT03521154 2026-02-27

LAURA

Phase 3 Active not recruiting

216 enrolled 25 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT03631199 2026-02-25

CANOPY-1

Phase 3 Terminated

673 enrolled 38 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT04738487 2026-02-20

Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)

Phase 3 Completed

1,264 enrolled 16 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03829332 2026-02-19

LEAP-007

Phase 3 Completed

623 enrolled 26 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT04665856 2026-02-13

SKYSCRAPER-02C

Phase 3 Active not recruiting

123 enrolled 26 charts

Small Cell Lung Carcinoma

NCT02542293 2026-02-12

NEPTUNE

Phase 3 Active not recruiting

953 enrolled 29 charts

Non Small Cell Lung Carcinoma NSCLC

NCT02152631 2026-02-06

JUNIPER

Phase 3 Active not recruiting

453 enrolled 18 charts

Carcinoma, Non-Small-Cell Lung

NCT02486718 2026-02-05

Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]

Phase 3 Active not recruiting

1,280 enrolled 24 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT05226598 2026-02-05

MK-7684A-007

Phase 3 Completed

739 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT05061823 2026-02-02

Bintrafusp Alfa Program Rollover Study

Phase 3 Completed

22 enrolled 11 charts

Lung Neoplasms, Neoplasms

NCT03456076 2026-01-30

A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer

Phase 3 Active not recruiting

257 enrolled 14 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT02411448 2026-01-16

RELAY

Phase 3 Active not recruiting

545 enrolled 24 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT02998528 2026-01-06

CheckMate 816

Phase 3 Completed

505 enrolled 17 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT05740566 2026-01-05

DeLLphi-304

Phase 3 Active not recruiting

509 enrolled 11 charts 2 FDA

Small Cell Lung Carcinoma

NCT04471428 2025-12-22

CONTACT-01

Phase 3 Completed

366 enrolled 24 charts

Carcinoma, Non-Small-Cell Lung

NCT03215706 2025-12-17

CheckMate 9LA

Phase 3 Completed

719 enrolled 21 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT03924869 2025-12-11

KEYNOTE-867

Phase 3 Terminated

448 enrolled 24 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT04063163 2025-12-09

A Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy in Patients With ES-SCLC

Phase 3 Completed

585 enrolled 14 charts

Small Cell Lung Carcinoma

NCT03735121 2025-12-05

A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Phase 3 Completed

438 enrolled 40 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT03052608 2025-11-25

A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

Phase 3 Active not recruiting

296 enrolled 28 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT03703297 2025-11-21

ADRIATIC

Phase 3 Active not recruiting

730 enrolled 19 charts 2 FDA

Carcinoma, Lung Neoplasms, Small Cell Lung Carcinoma

NCT01933932 2025-11-19

SELECT-1

Phase 3 Active not recruiting

510 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT06212752 2025-11-12

MK-3475A-D77

Phase 3 Active not recruiting

39 enrolled 21 charts

Carcinoma, Non-Small-Cell Lung

NCT02477826 2025-10-30

CheckMate 227

Phase 3 Completed

2,747 enrolled 21 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT03519971 2025-10-28

Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer

Phase 3 Active not recruiting

328 enrolled 23 charts

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT03906071 2025-10-21

SAPPHIRE

Phase 3 Completed

577 enrolled 22 charts

Metastatic Non-Squamous Non-Small Cell Lung Cancer

NCT04194944 2025-10-21

LIBRETTO-431

Phase 3 Active not recruiting

261 enrolled 24 charts

Carcinoma, Non-Small-Cell Lung